Forgot Password?
Return to Course Listing

CME: Ulcerative Colitis (UC): Optimizing Pharmacotherapeutic Management Strategies


Activity Description / Statement of Need:

In this online, self-learning activity:

Inflammatory bowel disease (IBD) is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are ulcerative colitis (UC) and Crohn’s disease (CD), the former of which exclusively affects the colon and rectum. UC occurs more frequently than CD, with an incidence of 1.2 to 20.3 cases per 100,000 persons per year and a prevalence of 7.6 to 246.0 cases per 100,000 per year, as compared to 0.03 to 15.6 and 3.6 to 214.0 per 100,000 for CD. Risk factors include characteristics common in westernized environments and lifestyles, including smoking, diets high in fat and sugar, medication use, stress, and high socioeconomic status.

Target Audience:

HCPs specializing in: gastroenterology, internal medicine; nurse practitioners, physician assistants, and pharmacists who specialize in gastroenterology; and those who otherwise commonly care for or clinically encounter patients with UC.

This program is supported by an educational grant from Amgen.

Release Date: July 22, 2020 -- Expiration Date: July 22, 2022

Faculty: Mark Mattar, MD


Faculty introduction, disclosures

Epidemiology and clinical features of UC

  • Statistics by severity
  • Causes and risk factors
  • Clinical features: endoscopic, radiologic, and histopathologic
  • Burden of disease, health-related quality of life

Treatment of UC

  • UC professional guidelines
  • Medications for induction and maintenance therapy for UC: salicylates, including novel formulations; glucocorticoids; immunomodulators; biologicals
  • Novel and emerging therapies and approaches to the treatment of UC
  • Adherence to therapy and modifiable factors that may exacerbate the disease course
  • The role of teaching and communication strategies in strengthening the patient-provider compact
  • Patient case(s)

Best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the burden of disease UC represents to patients.
  • Identify the present treatment options currently available for management of UC and apply them to patient cases using evidence-based medicine.
  • Identify new and emerging therapies for the treatment of UC.
  • Evaluate a treatment plan for a specific patient based on severity of UC to optimize safety, efficacy, and cost-efficacy, suggesting modifications for improvement.


ACCME Activity #201861260


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Mark C. Mattar, MD, FACG, AGAF, Associate Professor of Medicine, Director, Fellowship Training Program, Director, IBD Center, MedStar Georgetown University Hospital, has received financial compensation as a consultant and speakers bureau from AbbVie, Janssen, Takeda, and Pfizer. 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME, has no relevant conflicts of interest to disclose.

Commercial Support Disclosure: This program is supported by an educational grant from Amgen.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Ulcerative Colitis: Updates from the DDW 2019 Annual Meeting

Employing biosimilars in the treatment of inflammatory health conditions: How to and should I?

Pediatric Crohn's disease: Therapeutic updates and optimizing treatment

Short bowel syndrome: therapeutic updates and optimizing treatment